bcl-2/bax EXPRESSION AND p53 GENE STATUS IN HUMAN BLADDER CANCER

YE, DINGWEI; LI, HUI; QIAN, SONGXI; SUN, YINGHAO; Jiafu, Zheng; &NA;, YONGJIANG

doi:10.1097/00005392-199812010-00023

Cited by 6 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These proteins mainly regulate apoptosis at the mitochondrial outer membrane and control the initiation of mitochondrial outer membrane permeabilization (97). Studies have shown that Bcl-2 and Bax have a role in affecting drug-induced apoptosis and regulating the resistance to chemotherapy in various tumor cells, including hepatocellular carcinoma and bladder, lung and ovarian cancer (98–101). …”

Section: Apoptosis and Cell Cycle-related Gene Expression Turbulencementioning

confidence: 99%

Molecular mechanisms of chemoresistance in osteosarcoma (Review)

2014

View full text Add to dashboard Cite

Due to the emergence of adjuvant and neoadjuvant chemotherapy, the survival rate has been greatly improved in osteosarcoma (OS) patients with localized disease. However, this survival rate has remained unchanged over the past 30 years, and the long-term survival rate for OS patients with metastatic or recurrent disease remains poor. To a certain extent, the reason behind this may be ascribed to the chemoresistance to anti-OS therapy. Chemoresistance in OS appears to be mediated by numerous mechanisms, which include decreased intracellular drug accumulation, drug inactivation, enhanced DNA repair, perturbations in signal transduction pathways, apoptosis- and autophagy-related chemoresistance, microRNA (miRNA) dysregulation and cancer stem cell (CSC)-mediated drug resistance. In addition, methods employed to circumvent these resistance mechanism have been shown to be effective in the treatment of OS. However, almost all the current studies on the mechanisms of chemoresistance in OS are in their infancy. Further studies are required to focus on the following aspects: i) Improving the delivery of efficacy through novel delivery patterns; ii) improving the understanding of the signal transduction pathways that regulate the proliferation and growth of OS cells; iii) elucidating the signaling pathways of autophagy and its association with apoptosis in OS cells; iv) utilizing high-throughput miRNA expression analysis to identify miRNAs associated with chemoresistance in OS; and v) identifying the role that CSCs play in tumor metastasis and in-depth study of the mechanism of chemoresistance in the CSCs of OS.

show abstract

Section: Apoptosis and Cell Cycle-related Gene Expression Turbulencementioning

confidence: 99%

Molecular mechanisms of chemoresistance in osteosarcoma (Review)

2014

View full text Add to dashboard Cite

show abstract

“…Studies have shown that Bcl-2 and Bax play important roles in mediating drug-induced apoptosis and drug resistance in various tumor cells, including hepatocellular carcinoma, bladder, lung and ovarian cancer [20–23]. Here we show that RhoA inhibits drug-induced apoptosis by impacting on Bcl-2, Bcl-xl and Bax.…”

Section: Discussionmentioning

confidence: 48%

RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer

Huang

Zhang

Chong³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide. While surgery remains the mainstay of treatment in early stage CRC, chemotherapy is usually given to prolong the overall survival and improve the quality of life for metastatic colorectal cancer (mCRC). But drug resistance is one of the major hurdles of mCRC treatment, and the underlying mechanisms are still largely unknown. In this study, we show that, compared with parental cells, RhoA is up-regulated in irinotecan (CPT-11)-resistant CRC cells. Furthermore, inhibition of RhoA in drug resistant cells, at least partially, rescues the resistance against irinotecan and increases the sensitivity to other chemotherapeutic drug by inhibiting expression of MDR1, MRP1and GSTP1, promotes apoptosis by suppressing the expression of BCL-XL and Bcl-2 and increasing Bax expression, and significantly decreases side population cells. Our results suggest that, in addition to survival, proliferation, migration, adhesion, cell cycle and gene transcription, RhoA is also involved in chemoresistance by regulating the expression of membrane transporter and apoptosis protein in colorectal cancer. They raise an interesting possibility that the expression of RhoA may indicate a poor prognosis due to the high probability to therapy resistance and, on the other hand, inhibition of RhoA activity and function may overcome chemoresistance and improve the effectiveness of clinical treatment of CRC.

show abstract

“…Some studies suggest that these molecules contribute to disease aggressiveness and outcome in BC. However, the opposite results have also been found [ 32 , 37 , 53 ]. A higher Bcl-2/Bax ratio (>1) is associated with early recurrence after adjuvant intravesical chemotherapy [ 53 ].…”

Section: Apoptosis and Apoptosis-related Moleculesmentioning

confidence: 88%

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy

Miyata

Sakai

2015

Disease Markers

View full text Add to dashboard Cite

High recurrence rate is one representative characteristic of bladder cancer. Intravesical therapy after transurethral resection is often performed in patients with nonmuscle invasive bladder cancer (NMIBC) to prevent recurrence. Bacillus Calmette-Guérin (BCG) and several anticancer/antibiotic agents, such as mitomycin C and epirubicin, are commonly used for this therapy. BCG treatment demonstrates strong anticancer effects. However, it is also characterized by a high frequency of adverse events. On the other hand, although intravesical therapies using other anticancer and antibiotic agents are relatively safe, their anticancer effects are lower than those obtained using BCG. Thus, the appropriate selection of agents for intravesical therapy is important to improve treatment outcomes and maintain the quality of life of patients with NMIBC. In this review, we discuss the predictive value of various histological and molecular markers for recurrence after intravesical therapy in patients with NMIBC.

show abstract

bcl-2/bax EXPRESSION AND p53 GENE STATUS IN HUMAN BLADDER CANCER

Cited by 6 publications

References 12 publications

Molecular mechanisms of chemoresistance in osteosarcoma (Review)

Molecular mechanisms of chemoresistance in osteosarcoma (Review)

RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy

Contact Info

Product

Resources

About